Claims for Patent: RE37919

Summary for Patent: RE37919

Title:	Recombinant DNA method for production of parathyroid hormone
Abstract:	A recombinant DNA molecule coding for human parathyroid hormone operably linked to an inducible bacterial promoter, a leader growth hormone sequence, and a selective enzymatic cleavage site, expression of the molecule in bacteria, and methods for producing large quantities of human parathyroid hormone and its variants.
Inventor(s):	Kronenberg; Henry M. (Belmont, MA), Nussbaum; Samuel R. (Weston, MA), Doi; Tomoko (Nara, JP)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	08/790,584
Patent Claims:	1. A recombinant DNA molecule comprising: (a) an expression control region, said region in operable linkage with: (b) a leader sequence coding for human growth hormone amino acids 1-138 operably linked to: (c) a nucleotide sequence coding for a selective enzymatic cleavage site, said nucleotide sequence being linked to and preceding a genetic sequence coding for human parathyroid hormone (hPTH) or a polypeptide variant thereof having the capacity to bind to a receptor for hPTH. 2. The molecule of claim 1 wherein said control region includes a bacterial, viral, fungal, or mammalian promoter. 3. The molecule of claim 2 wherein said promoter is selected from the group consisting of the right promoter of bacteriophage .lambda. (P.sub.L), the left promoter of bacteriophage .lambda. (P.sub.R), the E. coli trp promoter, the E. coli recA promoter, the E. coli lacZ promoter, the E. coli lacI promoter, the E. coli gal promoter, the B. subtilis .alpha.-amylase promoter, the B. subtilis .alpha.-28-specific promoter, the promoters of the bacteriophages of Bacillus, and the Streptomyces promoters. 4. The molecule of claim 3 wherein said promoter is the E. coli trp promoter. 5. The molecule of claim 1 wherein said selective enzymatic cleavage site is cleaved by Factor Xa. 6. The molecule of claim 5 wherein said selective enzymatic cleavage site is Ile-Glu-Gly-Arg. 7. The molecule of claim 1 wherein said selective enzymatic cleavage site is cleaved by thrombin. 8. The molecule of claim 1 wherein said selective enzymatic cleavage site is Leu-Val-Pro-Arg. 9. The molecule of claim 8 wherein said human parathyroid hormone is hPTH (1-84). 10. The molecule of claim 8 wherein said polypeptide variant thereof having the capacity to bind to a receptor for hPTH is truncated at the N-terminus. 11. The molecule of claim 10 wherein said polypeptide variant thereof having the capacity to bind to a receptor for hPTH is selected from the group consisting of hPTH(2-84), hPTH(3-84), hPTH(4-84), hPTH(5-84), hPTH(6-84), hPTH(7-84), and hPTH(8-84). 12. The recombinant DNA molecule of claim 1 which is a plasmid. 13. The plasmid of claim 12 which is pGFP-1. 14. A host cell containing the molecule of claim 1. 15. The cell of claim 14 which is prokaryotic. 16. The cell of claim 15 which is bacterial. 17. The cell of claim 16 which is of the species E. coli. 18. The cell of claim 14 which is eukaryotic. 19. The cell of claim 18 which is a yeast cell or a mammalian cell. 20. A method of producing human parathyroid hormone (hPTH) or a polypeptide variant thereof having the capacity to bind to a receptor for hPTH, substantially free of natural contaminants, comprising: (a) providing the molecule of claim 7 in a host; (b) expressing said human parathyroid hormone or a polypeptide variant thereof having the capacity to bind to a receptor for hPTH thereof; and (c) obtaining a fusion protein containing a human growth hormone, fused to a selective enzymatic cleavage site, fused to hPTH(1-84) or a polypeptide variant thereof having the capacity to bind to a receptor for hPTH; and (d) cleaving said fusion protein of step (c) with an enzyme recognizing said selective enzymatic cleavage site. 21. The method of claim 20 further comprising: (f) purifying said hPTH(1-84) or said polypeptide variant thereof having the capacity to bind to a receptor for hPTH. 22. A fusion protein comprising: (a) a human growth hormone 1-138 fused to (b) a selective enzymatic cleavage site, fused to (c) hPTH(1-84) or a polypeptide variant thereof having the capacity to bind to a receptor for hPTH. 23. The protein of claim 22 wherein said selective enzymatic cleavage site is cleaved by Factor Xa. 24. The protein of claim 22 wherein said selective enzymatic cleavage site is Ile-Glu-Gly-Arg. 25. The protein of claim 22 wherein said selective enzymatic cleavage site is cleaved by thrombin. 26. The protein of claim 22 wherein said selective enzymatic cleavage site is Leu-Val-Pro-Arg. 27. The protein of claim 22 wherein said polypeptide variant thereof having the capacity to bind to a receptor for hPTH is selected from the group consisting of hPTH(2-84), hPTH(3-84), hPTH(4-84), hPTH(5-84, hPTH(6-84), hPTH(7-84), and hPTH(8-84). 28. The protein of claim 27 wherein said polypeptide variant thereof having the capacity to bind to a receptor for hPTH is hPTH(3-84)..Iadd. 29. The method of claim 21 wherein said hPTH(1-84) is purified using an HPLC RPC-18 system and is eluted with a linear 30-70% acetonitrile/H.sub.2 O gradient..Iaddend..Iadd. 30. Human parathyroid hormone substantially free of natural contaminants produced according to the method of claim 29..Iaddend.

Details for Patent RE37919

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2009-05-12